

High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology

Norm R. Campbell, MD, FRCPC;¹ Tej Khalsa, MD, MSc;² World Hypertension League Executive;³ Daniel T. Lackland, DrPH; Mark L. Niebylski, PhD, MBA, MS; Peter M. Nilsson, MD, PhD; Kimbree A. Redburn, MA; Marcelo Orias, MD; Xin-Hua Zhang, MD, PhD; International Society of Hypertension Executive;⁴ Louise Burrell, MD, MBChB, MRCP, FRACP; Masatsugu Horiuchi, MD, PhD; Neil R. Poulter, MBBS, MSc, FRCP, FMed Sci; Dorairaj Prabhakaran, MD, DM, MSc, FRCP, FNASc; Agustin J. Ramirez, MD, PhD; Ernesto L. Schiffrin, MD, PhD, FRSC, FRCPC; Rhian M. Touyz, PhD, MBBCh, FRCP, FRSE; Ji-Guang Wang, MD, PhD; Michael A. Weber, MD; World Stroke Organization;⁵ International Diabetes Federation;⁶ International Council of Cardiovascular Prevention and Rehabilitation;⁷ International Society of Nephrology^{6,8}

From the Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada;¹ Department of Medicine, University of Calgary, Calgary, Alberta, Canada;² WHL, Corvallis, MT;³ ISH Secretariat, c/o The Conference Collective Ltd., Teddington, Middlesex, UK;⁴ WSO Administrative Office, c/o Kenes International, Geneva 6, Switzerland;⁵ IDF, Brussels, Belgium;⁶ York University, Toronto, Ontario, Canada;⁷ and ISN, Cranford, NJ⁸

Increased blood pressure (BP) is the second leading risk factor for death and disability globally according to the Global Burden of Disease Study.¹

Increased BP was the cause of an estimated 10.3 million deaths and 208 million disability-adjusted life years in 2013 (1) and the cause of²⁻¹⁰:

- 50% of heart disease, stroke, and heart failure.
- 19% of deaths overall and more than 40% of deaths in persons with diabetes.
- Hypertension is a leading risk for fetal and maternal death in pregnancy, dementia, and renal failure.

Hypertension is a public health epidemic^{2,11,12}

- Approximately four in 10 adults older than 25 have hypertension, and in many countries another one in five have prehypertension.


- An estimated nine of 10 adults who live to 80 years will develop hypertension.
- One half of BP-related disease occurs in persons with higher levels of BP despite being within the normal range.

Hypertension now disproportionately impacts low- and middle-income countries²

- Two thirds of those with hypertension are in economically developing countries.
- Heart disease and stroke occur in younger persons in economically developing countries.

BP-related disease has a major impact on healthcare spending¹³

- An estimated 10% of healthcare spending is directly related to increased BP and its complications.



Address for correspondence: Mark Niebylski, WHL, 415 Bass Lane, Corvallis, MT 59828

E-mail: mniebylski@yahoo.com

DOI: 10.1111/jch.12840

- Nearly 25% of healthcare spending in Eastern Europe and Central Asia is caused by BP-related disease.

Unhealthy choices in unhealthy environments play a major role in increasing BP^{14,15}

- Unhealthy diet is estimated to be associated with about half of hypertension cases.
- About 30% of cases are associated with increased salt consumption and about 20% to low dietary potassium (low fruit and vegetable intake).
- A high ratio of saturated fats to polyunsaturated fatty acids also contributes to hypertension.
- Physical inactivity is associated with about 20% of hypertension cases.
- Obesity is associated with about 30% of hypertension cases.
- Excess alcohol consumption also causes hypertension.
- Being tobacco free is especially important for patients with hypertension.

Clinical interventions have not been systematically applied in both economically developed and developing countries^{2,16,17}

- About half of individuals with hypertension are unaware that their BP is high.
- Some of those who are aware that their BP is high remain untreated. Even when treated, most have suboptimally controlled BP.

Investments in prevention are often cost-saving¹⁸⁻²³

- Policy interventions at a population level to improve diet and physical activity are often cost-saving and allow persons to make healthy choices.
- Recommended policies to prevent or manage hypertension through improved diet and increased physical activity are outlined by the World Health Organization (WHO).
- The World Health Assembly has agreed to a 2025 goal of reducing hypertension by 25% and dietary sodium by 30%.

Investments in treatment and control are cost-effective if targeted to patients at higher risk^{24,25}

- Most patients with clinical hypertension have additional cardiovascular risks and/or evidence of BP-related damage (heart disease, stroke, and/or kidney damage).
- Treating increased BP in the range defined as hypertension ($\geq 140/90$ mmHg) is effective in reducing stroke and heart disease.
- Managing increased BP in persons at moderate to high risk for hypertension is cost-effective, and BP lowering to targets <140 mm Hg systolic (eg, <130 mm Hg or 120 mm Hg may need to be considered given emerging evidence^{26,27}).
- Normalizing BP in persons with diabetes is especially important to prevent kidney and eye disease as well

as heart attack and stroke. BP-lowering treatment in persons with diabetes and hypertension often provides cost savings.

- Management of hypertension should be based on an assessment of cardiovascular risk and can be integrated into programs to cost-effectively manage noncommunicable diseases.
- The recent Systolic Blood Pressure Intervention Trial (SPRINT) emphasize that, in general, lower BP levels are beneficial for most patients.²⁷

Policy Inertia

- Many countries have not implemented effective public policies to prevent and control hypertension (<http://www.wcrf.org/int/policy/nourishing-framework>).
- Some national hypertension organizations do not have policy statements and do not advocate for policies aligned with those developed by the WHO for the effective prevention and control of hypertension.

Clinical inertia²⁸

- Some national hypertension organizations do not have published strategic plans for diagnosing, treating, and controlling hypertension.
- Many clinicians do not routinely assess BP and do not initiate or titrate treatment in patients with elevated BP readings.

A TRANSFORMATIVE APPROACH TO REFOCUS EFFORTS ON PREVENTION AND CONTROL IS REQUIRED. THE WORLD HYPERTENSION LEAGUE RECOMMENDS THE FOLLOWING STEPS.

National Hypertension Organizations

- Develop strategic plans for the prevention and control of hypertension, national fact sheets, and calls to action.²⁹⁻³²
- Advocate for healthy public policies, especially those that reduce dietary salt/sodium and promote healthy diets and smoking cessation.²²
- Restructure hypertension meetings and congresses to drive a hypertension prevention and control agenda.³³
- Feature the role of food/salt industry financial conflicts of interest and the role of low-quality science in educational forums updating the science on dietary salt.³⁴⁻⁴⁰
- Work with community organizations to develop high-capacity BP screening programs that connect persons with high readings to health care.⁴¹
- Advocate for regulations to ensure the use of accurate and appropriate BP devices and cuffs.⁴²⁻⁴⁴
- Ensure that there are hypertension management guidelines adapted to the country's population. In low-resource settings, the WHO Package of Essential Noncommunicable program is effective and low cost.^{45,46}

- Develop resources to aid the implementation of hypertension guidelines such as simple, easy-to-use algorithms or care maps.
- Advocate for easy access to affordable antihypertensive drugs for all patients.⁴⁷
- Encourage the use of hypertension registries and performance feedback in clinics that care for patients with hypertension.
- Develop strong partnerships with the organizations that represent healthcare providers who diagnose and manage hypertension.
- Ensure that there is standardized monitoring and evaluation of efforts to prevent and control hypertension.⁴⁸
- Nominate deserving programs and individuals for World Hypertension League recognition awards for population salt reduction and blood pressure control (www.whleague.org).⁴⁹
- Recognize national/regional leaders and programs that prevent and control hypertension.

Healthcare professionals

- Measure BP at all relevant clinical encounters.
- Assess cardiovascular risk in patients diagnosed with hypertension.^{45,50}
- Treat patients at high cardiovascular risk to controlled BP levels.^{45,50}
- Assess tobacco use. Advise and assist all users to stop.
- Assess hypertensive disorders of pregnancy.
- Advocate for healthy public policy.
- Encourage and assist community BP screening programs.⁴¹

Individuals

- Eat unprocessed or minimally processed foods most often.
- Choose low-sodium options and do not add salt to food.
- Be tobacco free.
- Be physically active.
- Attain and maintain a healthy body weight.
- Avoid exceeding the recommendations for maximum daily and weekly alcohol intake.
- Get BP checked regularly and understand what it should be.
- Advocate for healthy public policies.

KEY MESSAGES

- Hypertension may often be preventable and remains a constant threat to patient well-being.
- There are effective policies that could facilitate people making healthy choices, and, if implemented, could largely prevent hypertension.
- Hypertension is easy to screen for BUT only about 50% of adults with hypertension are aware of their condition.
- Effective lifestyle and drug treatments are available that could control hypertension in most individuals.

Acknowledgments: This work is an updated version of the World Hypertension League (WHL) 2014 Hypertension Fact sheet² (www.whleague.org).

Disclosures: Dr Mark Niebylski and Kimbree Redburn are paid WHL consultants but report no other conflicts. Dr Ji-Guang Wang reports receiving research grants and consulting fees from several BP-measuring device companies including A&D, AVITA, Honsun, Omron, and Rossmax but reports no other conflicts. Dr Michael Weber is a consultant for and received travel support from Omron but reports no other conflicts. All other primary authors including those from WHL and the International Society of Hypertension report no conflicts of interest.

References

1. Institute for Health Metrics and Evaluation, 2015 University of Washington. <http://vizhub.healthdata.org/gbd-compare/>. Accessed December 22, 2015.
2. Campbell NR, Lackland DT, Niebylski ML; World Hypertension League Committee; International Society of Hypertension Executive Committee. High blood pressure: why prevention and control are urgent and important: a 2014 fact sheet from the World Hypertension League and the International Society of Hypertension. *J Clin Hypertens (Greenwich)*. 2014;16:551–553 doi: 10.1111/jch.12372. Epub 2014 Jul 17.
3. World Health Organization. *A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis. World Health Day 2013*. Geneva, Switzerland: World Health Organization; 2013.
4. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. *JAMA*. 1996;275:1557–1562.
5. Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. *Nat Rev Nephrol*. 2011;7:11–21.
6. Levi MN, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. *J Hypertens*. 2013;31:1073–1082.
7. Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. *Lancet*. 2006;367:1066–1074.
8. Seely EW, Maxwell C. Cardiovascular patient page. Chronic hypertension in pregnancy. *Circulation*. 2007;115:e188–e190.
9. Chen G, McAlister FA, Walker RL, et al. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. *Hypertension*. 2011;57:891–897.
10. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet* 2016;387:957–967.
11. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men. *JAMA*. 2002;287:1003–1010.
12. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. *Lancet*. 2008;371:1513–1518.
13. Gaziano TA, Bitton A, Anand S, Weinstein MC. The global cost of nonoptimal blood pressure. *J Hypertens*. 2009;27:1472–1477.
14. Committee on Public Health Priorities to Reduce and Control Hypertension in the U.S. Population, Institute of Medicine of the National Academies. *A Population-Based Policy and Systems Change Approach to Prevent and Control Hypertension*. Washington, DC: National Academies Press; 2010.
15. Nissinen A, Pietinen P, Tuomilehto J, et al. Predictors of blood pressure change in a series of controlled dietary intervention studies. *J Hum Hypertens*. 1987;1:167–173.
16. Perkovic V, Huxley R, Wu Y, et al. The burden of blood pressure-related disease: a neglected priority for global health. *Hypertension*. 2007;50:991–997.
17. Ibrahim MM, Damasceno A. Hypertension in developing countries. *Lancet*. 2012;380:611–619.
18. World Health Organization. *WHO Global Status Report on Noncommunicable Diseases 2010*. Geneva, Switzerland: WHO Press, World Health Organization; 2011.
19. Mozaffarian D, Afshin A, Benowitz NL, et al. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. *Circulation*. 2012;126:1514–1563.
20. Wilson JF. Can disease prevention save health reform? *Ann Intern Med*. 2009;151:145–148.
21. World Health Organization. *Diet, Nutrition and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation*. Geneva, Switzerland: World Health Organization; 2003. Report No.: 1.

22. World Health Organization. *WHO Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020*. Geneva, Switzerland: WHO Press, World Health Organization; 2013.
23. United Nations General Assembly. *Note by the Secretary-General Transmitting the Report of the Director-General of the World Health Organization on the Prevention and Control of Non-communicable Diseases*. New York, USA: Department for General Assembly and Conference Management; 2013 Dec 10.
24. National Clinical Guideline Centre. *Hypertension. Clinical management of primary hypertension in adults*. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Aug. 36 p. (Clinical guideline; no. 127).
25. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003;21:1983–1992.
26. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. *Lancet* 2016;387:435–443.
27. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103–2116.
28. Kotchen TA. The search for strategies to control hypertension. *Circulation*. 2010;122:1141–1143.
29. Campbell NRC, Niebylski M. Prevention and control of hypertension: developing a global agenda. *Curr Opin Cardiol*. 2014;29:324–330.
30. Campbell NR, Lackland DT, Lisheng L, et al. Using the global burden of disease study to assist development of nation-specific fact sheets to promote prevention and control of hypertension and reduction in dietary salt: a resource from the World Hypertension League. *J Clin Hypertens (Greenwich)*. 2015;17:165–167.
31. Campbell NR, Bove P, Schutte AE, et al. High blood pressure in sub-Saharan Africa: why prevention, detection, and control are urgent and important. *J Clin Hypertens (Greenwich)*. 2015;17:663–667.
32. Campbell NR, Lackland DT, Lisheng L, et al. The World Hypertension League challenges hypertension and cardiovascular organizations to develop strategic plans for the prevention and control of hypertension. *J Clin Hypertens (Greenwich)*. 2015;17:325–327.
33. Campbell NR, Redburn KA, Niebylski ML, et al. Restructuring hypertension congresses and scientific meetings for improved hypertension prevention and control. *J Clin Hypertens (Greenwich)*. 2016;18:169–171.
34. Campbell NR, Appel LJ, Cappuccio FP, et al. A call for quality research on salt intake and health: from the World Hypertension League and supporting organizations. *J Clin Hypertens (Greenwich)*. 2014;16:469–471.
35. Campbell NR, Lackland DT, MacGregor GA. Dietary sodium: a perspective on recent sodium evidence—its interpretation and controversies. *J Clin Hypertens (Greenwich)*. 2013;15:765–768.
36. Campbell NR, Lackland DT, Niebylski ML. 2014 Dietary salt fact sheet of the World Hypertension League, International Society of Hypertension, Pan American Health Organization technical advisory group on cardiovascular disease prevention through dietary salt reduction, the World Health Organization collaborating centre on population salt reduction, and World Action on Salt & Health. *J Clin Hypertens (Greenwich)*. 2015;17:7–9.
37. Johnson C, Raj TS, Trudeau L, et al. The science of salt: a systematic review of clinical salt studies 2013 to 2014. *J Clin Hypertens (Greenwich)*. 2015;17:401–411.
38. Campbell NR, Lackland DT, Niebylski ML, Nilsson PM. Is reducing dietary sodium controversial? Is it the conduct of studies with flawed research methods that is controversial? A perspective from the World Hypertension League executive. *J Clin Hypertens (Greenwich)*. 2015;17:85–86.
39. Campbell NR, Correa-Rotter R, Cappuccio FP, et al. Proposed nomenclature for salt intake and for reductions in dietary salt. *J Clin Hypertens (Greenwich)*. 2015;17:247–251.
40. Campbell N, Lackland D, Chockalingam A, et al. The World Hypertension League and International Society of Hypertension call on governments, nongovernmental organizations, and the food industry to work to reduce dietary sodium. *J Clin Hypertens (Greenwich)*. 2014;16:99–100.
41. Mangat BK, Campbell N, Mohan S, et al. Resources for blood pressure screening programs in low resource settings: a guide from the world hypertension league. *J Clin Hypertens (Greenwich)*. 2015;17:418–420.
42. Campbell NR, Barbari AE, Cloutier L, et al. Policy statement of the World Hypertension League on noninvasive blood pressure measurement devices and blood pressure measurement in the clinical or community setting. *J Clin Hypertens (Greenwich)*. 2014;16:320–322.
43. Campbell NR, Niebylski ML, Redburn K, et al. World Hypertension League position on public use of blood pressure kiosks. *J Clin Hypertens (Greenwich)*. 2015;17:913.
44. Campbell NRC, Gelfer M, Stergiou GS, et al. A call to regulate manufacture and marketing of blood pressure devices and cuffs. A position statement from the World Hypertension League, International Society of Hypertension and supporting hypertension organizations. *J Clin Hypertens (Greenwich)*. 2016;18:378–380.
45. World Health Organization. *WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low-Resource Settings*. Geneva, Switzerland: World Health Organization; 2010.
46. Zhang XH, Lisheng L, Campbell NR, et al. Implementation of World Health Organization Package of Essential Noncommunicable disease interventions (WHO PEN) for primary health care in low-resource settings: a policy statement from the World Hypertension League. *J Clin Hypertens (Greenwich)*. 2016;18:5–6.
47. Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. *Lancet*. 2016;2:61–69.
48. Gee ME, Campbell N, Sarrafzadegan N, et al. Standards for the uniform reporting of hypertension in adults using population survey data: recommendations from the World Hypertension League expert committee. *J Clin Hypertens (Greenwich)*. 2014;16:773–781.
49. Redburn KA, Niebylski ML. Excellence and notable achievement awards from the World Hypertension League: a call for 2015 nominations. *J Clin Hypertens (Greenwich)*. 2014;16:928–929.
50. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. *J Clin Hypertens (Greenwich)*. 2014;16:14–26.